KELYNIAM GLOBAL INC - KLYG STOCK NEWS

Kelyniam Global (OTC: KLYG) reported a significant improvement in its Q1 financials for the quarter ending March 31, 2024. Revenue increased by 60.5% to $957,447, while the gross margin rose by 59.0% to $743,719. The company achieved an operating profit of $123,599, a notable turnaround from a loss of $67,978 in the same period last year, largely due to decreased consulting and IT costs. Surgeons and distributors increasingly use Kelyniam's custom cranial and craniofacial implants, contributing to sales momentum from Q4 into Q1. Interest in the CustomizedBone hydroxyapatite osteo-integrative cranial implant is growing, especially for pediatric patients, boosted by the approval of the NEOS Cranial Loop fixation method. The annual Shareholder Meeting will be held on June 24 at 8:30 am Central. Full financial details are available on the company's website.

Kelyniam Global and Fin-ceramica's NEOS Surgery Cranial LOOP™ fixation system receives 510(k) clearance from the FDA for use with CustomizedBone™ hydroxyapatite cranial implants. The system, made of PEEK-OPTIMA™, offers rapid fixation, low infection rate, and pediatric indication, enhancing Kelyniam's sales momentum.

Kelyniam Global (KLYG) reported a 12% decrease in total revenue for the year ended December 31, 2023, despite setting a quarterly unit sales record in Q4. The company attributed the revenue decline to strategic investments in personnel and infrastructure earlier in the year. The CEO highlighted a 40% unit and revenue growth in Q4, driven by new sales representatives and a competitor's exit from the market. Kelyniam aims to capitalize on this opportunity by offering innovative implant solutions.

Kelyniam Global (OTC:KLYG) reports third-quarter results with a temporary sales slowdown but remains optimistic.

Kelyniam Global (OTC:KLYG) announced its half-year financial results, reporting flat unit sales for the first half of 2023 compared to the previous year. The company attributes this to timing issues affecting revenue recognition. Despite this, the CEO remains optimistic about sales and revenue growth in the latter half of the year. Financial highlights include a 21.9% decrease in total revenue, a decrease in gross margin, and an operating loss compared to operating income in the prior year.

Kelyniam Global (OTC: KLYG), a manufacturer of custom cranial implants, reported a 13.2% increase in total revenue for 2022, reaching $3,017,599 compared to $2,664,434 in 2021. However, the company recorded a net loss of $97,560 after posting a net income of $201,741 in the previous year. The decline in profitability was attributed to non-cash legacy stock awards and operating income fell to $69,322 from $180,445. CEO Ross Bjella highlighted the company's competitive edge in manufacturing and rapid delivery of custom implants and outlined plans for future product development and licensing in the neurosurgery market.

Kelyniam Global (OTC:KLYG) announced strong third-quarter results for the period ending September 30, 2022. Total revenue reached $2,194,435, marking a 12.3% increase year-over-year, with a gross margin of $1,738,733, up 16.4%. However, operating income decreased to $93,523 from $140,568 due to ongoing investments in infrastructure and regulatory consulting. Kelyniam also formed a partnership with Singular Health (ASX:SHG) as their Registered Agent in the U.S. following the 510(k) clearance of their innovative 3DiCom MD software.

Kelyniam Global (OTC:KLYG), a producer of custom cranial implants, reported a strong Q2 2022 with a 20% revenue increase to $1,469,354, compared to $1,224,059 in Q2 2021. The CustomizedBone® implant significantly contributed to this growth. Operating income was $38,394, slightly down from $47,167 in the same period last year. Investments in infrastructure and marketing were funded without additional debt. The company anticipates continued sales momentum and benefits from returning surgical activity trends.